within Pharmacolibrary.Drugs.ATC.A;

model A10AE54
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10AE54</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Insulin glargine and lixisenatide is a fixed-ratio combination product used for the treatment of type 2 diabetes mellitus. Insulin glargine is a long-acting insulin analog, while lixisenatide is a GLP-1 receptor agonist. The combination helps to improve glycemic control in adults whose blood sugar is not adequately managed by either agent alone. The combination is approved and marketed as Soliqua (EU/US).</p><h4>Pharmacokinetics</h4><p>No direct pharmacokinetic publications were found for the fixed-ratio combination. Individual PK parameters for insulin glargine and lixisenatide monotherapy in healthy and type 2 diabetes adults have been used as estimates.</p><h4>References</h4><ol><li><p>Inoue, M, et al., &amp; Hashimoto, Y (2019). Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial. <i>Diabetes, obesity &amp; metabolism</i> 21(8) 2001–2005. DOI:<a href=\"https://doi.org/10.1111/dom.13757\">10.1111/dom.13757</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31050109/\">https://pubmed.ncbi.nlm.nih.gov/31050109</a></p></li><li><p>Gautier, T, et al., &amp; Breton, MD (2022). Modeling the Effect of Subcutaneous Lixisenatide on Glucoregulatory Endocrine Secretions and Gastric Emptying in Type 2 Diabetes to Simulate the Effect of iGlarLixi Administration Timing on Blood Sugar Profiles. <i>Journal of diabetes science and technology</i> 16(2) 428–433. DOI:<a href=\"https://doi.org/10.1177/19322968211015671\">10.1177/19322968211015671</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34013770/\">https://pubmed.ncbi.nlm.nih.gov/34013770</a></p></li><li><p>Xie, P, et al., &amp; Shi, A (2023). Pharmacokinetics and Safety of iGlarLixi in Healthy Chinese Participants: Results of a Phase 1 Randomized Study. <i>Diabetes therapy : research, treatment and education of diabetes and related disorders</i> 14(8) 1387–1397. DOI:<a href=\"https://doi.org/10.1007/s13300-023-01434-0\">10.1007/s13300-023-01434-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37329393/\">https://pubmed.ncbi.nlm.nih.gov/37329393</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10AE54;
